U.S. court upholds patents on Pfizer's cancer drug

A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.

Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.

Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year.

The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS.

Tags
Pfizer, Mylan
Join the Discussion
Related Articles
More Home News
Married Couples, To File Joint or Separate Returns? Find Out What's Best

Married Couples, To File Joint or Separate Returns? Find Out What's Best

How To Prepare for Survivor's Penalty and Avoid Higher Taxes After Losing a Spouse

How To Prepare for Survivor's Penalty and Avoid Higher Taxes After Losing a Spouse

Wisconsin Legislation Introduces New $4000 Child Tax Credit, Aiding Families Statewide

Wisconsin Legislation Introduces New $4000 Child Tax Credit, Aiding Families Statewide

How to Maximize Social Security Benefits: Insights into Eligibility, Timing, and Claim Strategy

How to Maximize Social Security Benefits: Insights into Eligibility, Timing, and Claim Strategy

Real Time Analytics